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Two series of cycloalkanespiro-5-hydantoins, namely cyclohexanespiro-5-hydantoins and 
cycloheptanespiro-5-hydantoins with a 4-substituted b nzyl or a 2-(4-substituted phenyl)-2-
oxoethyl group at N3 position, were synthesized and their effects on proliferation of human 
colon (HCT-116), leukemia (K562) and breast (MDA-MB-231) cancer cell lines were tested. 
For comparison, we also described the 5,5-diphenylhydantoin analogues. The structural 
features of the investigated compounds were characterized by elemental analysis, FT-IR, UV-
Vis, 1H and 13C NMR spectroscopy and X-ray crystallography. Regarding their structure–
activity relationships, it was shown that the substitution on the benzyl moiety with the 
methoxy, chloro or bromo group potentiated the antiprol ferative activity relative to the 
parent compounds, while an increase in the size of the cycloalkyl group resulted mostly in a 
decrease of the antiproliferative activity. The single crystal X-ray analysis revealed the 
existence of dimers and chains formed by the N–H···O hydrogen bonds. The analysis of the 
molecular descriptors of Lipinski demonstrated that all investigated compounds obeyed the 
rule of five. To further understand their geometry and electronic structure, DFT calculations 
with B3LYP method using 6-311++G(d,p) basic set were performed. In this context, the UV-
Vis spectra of the investigated compounds were analyzed in detail, whereby the predicted 
absorption spectra from DFT calculation matched the experimentally obtained ones, with a 
good correlation. The interesting physico-chemical and pharmacologically relevant properties 
of the investigated compounds warrant their further investigation. 
 


























A number of reasons have been put forward to promote the pharmacological applications of 
derivatives of hydantoin (imidazolidine-2,4-dione) [1]. These compounds are mostly small 
molecules, lipophilic and easily penetrate biological membranes. When properly substituted, 
derivatives of hydantoin exhibit various pharmacological activities, e.g. anticonvulsant [2] 
antiarrhythmic [3], antiviral [4], anti-inflammatory [5] and anti-HIV activity [6]. A 
representative example of a hydantoin-based drug is phenytoin (5,5-diphenylhydantoin, 
Dilantin), which is widely used in the control of the grand mal types of epilepsy and cardiac 
arrhythmias [7]. 
Due to their ability to interfere with multiple signaling pathways influencing cancer 
metastasis, derivatives of hydantoin have been recognized as promising therapeutic agents in 
the cancer treatment. The non-steroidal antiandrogen nilutamide (3-(4-nitro-3-
trifluoromethylphenyl)-5,5-dimethylhydantoin, Nilandron), is used in combination with 
surgical castration for the treatment of metastatic prostate cancer [8]. Its ferrocenyl-aryl-
hydantoin derivatives have been shown to retain a modest affinity for the androgen receptor, 
while the N-substituted complexes show a weak or moderate antiproliferative effect on 
hormone-dependent and -independent prostate cancer cells [9]. A linkage of aryl hydantoin-
based antiandrogen through a short polyethylene glycol linker to genistein results in a 
conjugate which derives its antiproliferative activity against prostate cancer cell lines in a 
similar manner [10].  
The 5-benzylidene hydantoin core has also been recognized as a promising scaffold to 
develop new antiproliferative compounds. Carmi et al. have reported that 5-arylidene 
hydantoins inhibit the EGFR kinase and exhibited an antiproliferative action on A431 human 
epidermoid carcinoma cells [11]. Regarding the mechanism of action, their growth-inhibitory 
effects in the lung (A549) cancer cell line has been associated with an accumulation of the 
cells in the S phase of the cell cycle and induction of genomic DNA damage [12]. Z-5-(4-
Hydroxyphenyl)methylene hydantoin, a marine natural product, and its derivatives enhance 
tight junction formation and exhibit anti-invasive and anti-migratory activities in vitro against 
metastatic prostate cancer cells and inhibit tumor gr wth in distant organs in mouse models 
[13]. The corresponding structure–activity (SAR) studies have revealed the importance of 
size and lipophilic parameters, whereby log P and molecular volume are the most influential 
descriptors [14]. Jiang and Zeng have synthesized a series of structurally related hydantoin 
















dione) has been developed to cross the blood-brain b rrier; thus it has been reported to 
preferentially localize in brain tumors relative to n rmal brain tissue [16]. Several diversely 
substituted diazaspiro hydantoins show growth inhibitory effects against human breast (MCF-
7), hepatocellular (HepG-2), cervix (HeLa) and colon (HT-29) cancer cell lines [17]. In this 
case, substitution at N3 position in the hydantoin ring appears to have a key role in the 
antiproliferative activity, i.e., compounds bearing the aryl groups show better inhibition 
relative to those with the alkyl substituents. When additionally investigating the inhibition of 
the leukemia (K562) cell proliferation, Kavitha et al. have reported that the most promising 
candidate among these compounds induces cell apoptosis through mitochondrial pathway 
following cell cycle arrest [18]. Hydantoin derivatives of the dihydrothieno[2,3-b]naphtho-
4,9-dione system with a distal amine moiety exhibit a similar or greater cytotoxic potency 
than doxorubicin, a standard chemotherapy drug, against the human breast (MCF-7) and 
colon (SW 620) cancer cell lines [19]. Their cytotoxicity might be ascribed, among others, to 
an electrostatic interaction of the positively charged ammonium cation with a negatively 
charged binding site. Spiro bisheterocycles containing the hydantoin moiety have been shown 
to promote apoptosis of breast (MCF-7 and MDA-MB-23) cancer cell lines via p53-
dependent and -independent pathways [20]. 
Alanazi et al. have reported that 5,5-diphenylhydantoins with an alkyl, aryl or 
phenacyl group at N3 position possess selective activity against the renal (A498 and UO31) 
cancer cell lines [21]. The introduction of an additional piperydinyl unit has resulted in a 
compound which shows the strong activity against the melanoma (MDA-MB-435) and breast 
(MCF-7) cancer cell lines. The docking study has revealed that the hydantoin moiety binds to 
a narrow hydrophobic pocket in the enzyme through formation of the hydrogen bonds, while 
the π–π and π–cation interactions between the compound and the binding site have also been 
observed. In this context, we have shown that 3-(4-substituted benzyl)-5,5-diphenyl- and 3-
(4-substituted benzyl)-5-ethyl-5-phenylhydantoins exhibit the superior antiproliferative 
activity against breast (MDA-MB-231) cancer cell line than against colon (HCT-116) cancer 
cell line, whereby compounds bearing two phenyl groups at C5 position possess higher 
potencies than those with one phenyl group [22]. 
In the present study, two series of cycloalkanespiro-5-hydantoins bearing a                            
4-substituted benzyl or a 2-(4-substituted phenyl)-2-oxoethyl group at N3 position were 
synthesized (Figure 1, Series 1 and 2) and their effects on proliferation of human colon 















focus was thus placed on the overall effects of the structural modifications at N3 and C5 
positions of the hydantoin ring on the observed activity. In this context, we described the 
antiproliferative activities of several key compounds from our previous study [22] and the 
study of Alanazi [21], 3-(4-substituted benzyl)-5,5-diphenylhydantoins and 3-(2-(4-
substituted phenyl)-2-oxoethyl)-5,5-diphenylhydantoi s (Fig. 1, Series 3), against human 
colon (HCT-116) and breast (MDA-MB-231) cancer cell lines and additionally determined 
their antiproliferative activities against leukemia (K562) cancer cell line in this study. To 
understand the geometry and electronic structure of investigated hydantoin derivatives, DFT 
calculations with B3LYP method using 6-311++G(d,p) basic set were performed. Coupled 
with the single crystal X-ray analysis of the representative compounds (1c and 2a), the 
presented study provided basis for understanding of a structure–activity relationship of the 






2. Experimental section 
2.1. Chemistry 
The 1H and 13C NMR spectral measurements were performed on a Bruker AC 250 
spectrometer at 200 MHz for the 1H NMR and 50 MHz for the 13C NMR spectra or on a 
Bruker 300 spectrometer at 400 MHz for the 1H NMR and 100 MHz for the 13C NMR 
spectra. The spectra were recorded at room temperatur  in DMSO-d6. The chemical shifts 
were expressed in ppm values referenced to TMS (δH = 0 ppm) in 
1H NMR spectra, and the 
residual solvent signal (δC = 39.5 ppm) in 
13C NMR spectra. FT-IR spectra were recorded 
using a Bomem MB series 100 spectrophotometer (υmax are given in cm
-1) in the form of KBr 
pellets. The UV-Vis spectra were measured with a Shimadzu 1700 spectrophotometer. The 
elemental analyses of the investigated compounds were carried out by standard analytical 


















2.1.1. General procedure for the preparation of 1a−1g and 2a−2g 
The compounds of series 1 and 2 were obtained following the synthetic protocol shown in 
Scheme 1. 1,3-Diazaspiro[4.5]decane-2,4-dione and 1,3-diazaspiro[4.6]undecane-2,4-dione 
were synthesized according to the modified procedure of Bucherer and Lieb [23]. The 
compounds 1a−1i and 2a−2i were prepared using a modified procedure described pr viously 
[24]. 1,3-Diazaspiro[4.5]decane-2,4-dione or 1,3-diazaspiro[4.6]undecane-2,4-dione (0.01 
mol) and potassium carbonate (0.03 mol) were dissolved in DMF (60 cm3). After half an 
hour, 4-substituted benzyl halide (0.011 mol) was added in the solution. The reaction mixture 
was heated at 80 °C for three days. The reaction mixture was poured into three times the 
volume of water and extracted with ethyl acetate. The organic layer was washed with 5 % 
sodium hydroxide and water and dried over anhydrous magnesium sulphate. The residual 
solvent was removed by distillation and the crude product was purified by recrystallization 
from ethanol. 
<Scheme 1> 
2.1.2. General procedure for the preparation of 1h, 1i, 2h, 2i, 3h, 3i 
The compounds 1h, 1i, 2h, 2i, 3h and 3i were prepared according to the procedure given in 
[21] (Scheme 2). A mixture of the appropriate hydantoin (cycloalkanespiro-5-hydantoin or 
5,5-diphenylhydantoin) (0.01 mol) and potassium carbonate (0.01 mol) was stirred in 
acetone (60 cm3) at room temperature for half an hour. A solution f 1-(4-substituted 
phenyl)-2-chloroethanone (0.011 mol) in acetone wasadded and the reaction mixture was 





Yield 73%; White solid; mp 151−153 °C; FT-IR (KBr pill, ν cm-1) 3323 (NH), 1771, 1708 
(C=O); 1H NMR (200 MHz, DMSO−d6): δ /ppm =  8.81 (s, 1H, NH), 7.33−7.19 (m, 5H, 
−C6H5−), 4.52 (s, 2Н, –CH2–), 1.68−1.26 (m, 10H, −C6H10−); 
13C NMR (50 MHz, DMSO  ̶
d6): δ/ppm = 176.8, 155.9, 137.2, 128.8, 127.6, 127.2, 61.3, 41.0, 38.5, 24.6, 21.0; Elemental 


















Yield 56%; White solid; mp 211−213 °C; FT-IR (KBr pill, ν cm–1) 3220 (NH), 1771, 1704 
(C=O); 1H NMR (200 MHz, DMSO ̶ d6): δ/ppm = 8.79 (s, 1H, NH), 7.13 (d, J = 10 Hz, 2H, 
−C6H4−), 7.08 (d, J = 8 Hz, 2H, −C6H4−), 4.46 (s, 2H, −CH2−), 2.26 (s, 3H, −CH3), 
1.66−1.25 (m, 10H, −C6H10−); 
13C NMR (50 MHz, DMSO ̶ d6): δ/ppm = 176.9 155.9, 136.7, 
134.2, 129.4, 127.3, 61.3, 40.8, 33.5, 24.4, 21.0, 20.9 (2C); Elemental anal. calc. (%) for 
C16H20N2O2: C, 70.56; H ,7.40; N, 10.29; found: C, 70.62; H, 7.42; N, 10.34.  
 
3-(4-Methoxybenzyl)-1,3-diazaspiro[4.5]decane-2,4-dione (1c) 
Yield 58%; White solid; mp 162−165 °C; FT-IR (KBr pill, ν cm–1): 3295 (NH), 1773, 1696 
(C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm = 8.77 (s, 1H, NH), 7.17 (d, 2H, J = 8 Hz, 
−C6H4−), 6.89 (d, 2H, J = 8 Hz, −C6H4−), 4.46 (s, 2H, –CH2–), 3.73 (s, 3H, −CH3), 
1.62−1.26 (m, 10H, −C6H10−); 
13C NMR (50 MHz, DMSO−d6): δ/ppm = 176.8, 158.8, 
155.9, 129.2, 128.8, 114.1, 61.2, 55.2, 40.5, 33.5, 24.6, 21.00; Elemental anal. calc. (%) for 
C16H20N2O3: C, 66.65; H, 6.99; N, 9.72; found: C, 66.76; H, 7.04; N, 9.65. 
 
3-(4-Chlorobenzyl)-1,3-diazaspiro[4.5]decane-2,4-dione (1d) 
Yield 66%; White solid mp 185−186° °C; FT-IR (KBr pill, ν cm–1): 3232 (NH), 1773, 1710 
(C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm = 8.83 (s, 1H, NH), 7.40 (d, J = 8 Hz, 2H, 
−C6H4−), 7.24 (d, J = 8 Hz, 2H, −C6H4−), 4.52 (s, 2H, −CH2−), 1.68−1.03 (m, 10H, 
−C6H10−); 
13C NMR (50 MHz, DMSO−d6): δ/ppm = 176.8, 155.7, 136.1, 132.2, 129.3, 
128.8, 61.3, 40.4, 33.5, 24.6, 21.0; Elemental anal. calc. (%) for C15H17N2O2Cl: C, 61.54; H, 
5.85; N, 9.57; found: C, 61.57; H, 5.89; N, 9.52. 
 
3-(4-Bromobenzyl)-1,3-diazaspiro[4.5]decane-2,4-dione (1e) 
Yield 70%; White solid; mp 193−194 °C; FT-IR (KBr pill, ν cm–1): 3216 (NH), 1768, 1709 
(C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm = 8.83 (s, 1H, NH), 7.53 (d, J = 10 Hz, 2H, 
−C6H4−), 7.18 (d, J = 8 Hz, 2H, −C6H4−), 4.50 (s, 2H, −CH2−), 1.67−1.03 (m, 10H, 
−C6H10−); 
13C NMR (50 MHz, DMSO−d6): δ/ppm = 176.8, 155.7, 136.6, 131.7, 129.6, 
120.7, 61.3, 40.5, 33.5, 24.6, 21.0; Elemental anal. calc. (%) for C15H17N2O2Br : C, 53.43; H, 


















Yield 52%; White solid; mp 179−182 °C; FT-IR (KBr pill, ν cm–1): 3243 (NH), 2231 (CN), 
1771, 1714 (C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm = 8.88 (s, 1H, NH), 7.81 (d, 2H, 
J = 8 Hz, −C6H4−), 7.40 (d, 2H, J = 8 Hz, −C6H4−), 4.62 (s, 2H, –CH2–), 1.70−1.03 (m, 10H, 
−C6H10−); 
13C NMR (50 MHz, DMSO−d6): δ/ppm = 176.9, 155.6, 142.7, 132.8, 128.1, 
118.9, 110.4, 61.5, 40.7, 33.5, 24.5, 21.0; Elemental anal. calc. (%) for C16H17N3O2: C, 
67.83; H, 6.05; N, 14.83; found: C, 67.90; H, 6.05; N, 14.83. 
 
3-(4-Nitrobenzyl)-1,3-diazaspiro[4.5]decane-2,4-dione (1g) 
Yield 74%; Yellowish solid; mp 185−188 °C; FT-IR (KBr pill, ν cm–1): 3235 (NH), 1772, 
1708 (C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm = 8.90 (s, 1H, NH), 8.21 (d, 2H, J = 10 
Hz, −C6H4−), 7.49 (d, 2H, J = 8 Hz, −C6H4−), 4.68 (s, 2H, −CH2–), 1.70−1.03 (m, 10H, 
−C6H10−); 
13C NMR (50 MHz, DMSO−d6):  δ/ppm = 176.9, 155.6, 147.0, 144.8, 128.4, 
124.0, 61.5, 40.6, 33.4, 24.5, 21.0; Elemental anal. calc. (%) for C15H17N3O4: C, 59.40; H, 
5.65; N, 13.85; found: C, 59.32; H, 5.60; N, 13.94. 
 
3-(2-(4-Fluorophenyl)-2-oxoethyl)-1,3-diazaspiro[4.5]decane-2,4-dione (1h) 
Yield 40%; White solid; mp 177−180 °C; FT-IR (KBr pill, ν cm–1): 3301 (NH), 1765, 1716, 
1701 (C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm = 8.85 (s, 1H, NH), 8.13 (q, 2H, J = 
3.2 Hz, −C6H4−), 7.40(t, 2H, J = 9 Hz, −C6H4−), 4.92 (s, 2H, –CH2–), 1.79−1.28 (m, 10H, 
−C6H10−); 
13C NMR (50 MHz, DMSO−d6): δ/ppm = 191.3, 177.1, 165.8 (d, J = 251.5 Hz), 
155.9, 131.5 (d, J = 9.5 Hz), 131.1 (d, J = 2.5 Hz), 116.4 (d, J = 22 Hz), 61.7, 44.4, 33.6, 
24.6, 21.1; Elemental anal. calc. (%) for C16H17FN2O3: C, 63.15; H, 5.63; N, 9.21; found: C, 
63.04; H, 5.60; N, 9.16. 
 
3-(2-(4-Chlorophenyl)-2-oxoethyl)-1,3-diazaspiro[4.5]decane-2,4-dione (1i) 
Yield 45%; White solid; mp 248−250 °C; FT-IR (KBr pill, ν cm–1): 3109 (NH), 1777, 1708, 
1697 (C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm =  8.85 (s, 1H, NH), 8.05 (d, 2H, J = 8 
Hz, −C6H4−), 7.64 (d, 2H, J = 8 Hz, −C6H4−), 4.92 (s, 2H, –CH2–), 1.79−1.29 (m, 10H, 
−C6H10−); 
13C NMR (50 MHz, DMSO−d6): δ/ppm) = 191.8, 177.0, 155.6, 139.4, 133.0, 
130.3, 129.4, 61.7, 44.4, 33.6, 24.6, 21.0; Elemental anal. calc. (%) for C16H17N2O3Cl: C, 


















Yield 63%; White solid;  mp 117−118 °С; FT-IR (KBr pill, ν cm–1): 3233 (NH), 1771, 1703 
(C=O); 1H NMR (200 MHz, DMSO−d6):  δ/ppm = 8.66 (s, 1H, NH), 7.37−7.18 (m, 5H, 
−C6H5−), 4.51 (s, 2H, –CH2–), 1.86−1.56 (m, 12H, −C7H12−); 
13C NMR (50 MHz, 
DMSO−d6): δ/ppm = 178.0, 155.7, 137.2, 128.8, 127.6, 127.2, 63.9, 41.0, 37.2, 28.9, 22.3; 
Elemental anal. calc. (%) for C16H20N2O2: C, 70.56; H, 7.40; N, 10.29; found: C, 70.52; H, 
7.44; N, 10.26. 
 
3-(4-Меthylbenzyl)-1,3-diazaspiro[4.5]decane-2,4-dione (2b) 
Yield 56%; White solid; mp 172 ̶ 175 °С; FT-IR (KBr pill, ν cm–1): 3238 (NH), 1769, 1702 
(C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm =  8.64 (s, 1H, NH), 7.16 (d, 2H, J = 8 Hz, 
−C6H4−), 7.10 (d, 2H, J = 8 Hz, −C6H4−), 4.46 (s, 2H, −CH2–), 2.27 (s, 3H, −CH3), 
1.81−1.59 (m, 12H, −C7H12−); 
13C NMR (50 MHz, DMSO−d6): δ/ppm = 178.0, 155.7, 
136.7, 134.2, 129.3, 127.3, 63.8, 40.8, 37.1, 28.9, 22.2, 20.8;  Elemental anal. calc. (%) for 
C17H22N2O2: C, 71.30; H, 7.74; N, 9.78; found: C, 70.28; H, 7.80; N, 9.75. 
 
3-(4-Methoxybenzyl)-1,3-diazaspiro[4.5]decane-2,4-dione (2c) 
Yield 53%; White solid; mp 132−134 °С; FT-IR (KBr pill, ν cm–1): 3259 (NH), 1767, 1706 
(C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm = 8.61 (s, 1H, NH), 7.15 (d, 2H, J = 8 Hz, 
−C6H4−), 6.88 (d, 2H, J = 8 Hz, −C6H4−), 4.42 (s, 2H, −CH2−), 3.73 (s, 3H, −CH3), 
1.84−1.57 (m, 12H, −C7H12−); 13C NMR (50 MHz, DMSO−d6): δ/ppm = 178.0, 158.8, 
155.8, 129.2, 128.9, 114.2, 63.8, 55.3, 40.5, 37.15, 28.9, 22.3; Elemental anal. calc. (%) for 
C17H22N2O3: C, 67.53; H, 7.33; N, 9.26; found: C, 67.50; H, 7.37; N, 9.23. 
 
3-(4-Chlorobenzyl)-1,3-diazaspiro[4.5]decane-2,4-dione (2d) 
Yield 65%; White solid; mp 170−173 °С; FT-IR (KBr pill, ν cm–1): 3231 (NH), 1769, 1721 
(C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm = 8.68 (s, 1H, NH), 7.39 (d, J = 8.4 Hz, 2H, 
−C6H4−), 7.23 (d, J = 8.6 Hz, 2H, −C6H4−), 4.49 (s, 2H, −CH2−), 1.85−1.55 (m, 12H, 
−C7H12−); 
13C NMR (50 MHz, DMSO−d6): δ/ppm = 178.0, 155.6, 136.2, 132.2, 129.3, 
128.8, 63.9, 40.4, 37.1, 28.9, 22.3; Elemental anal. calc. (%) for C16H19N2O2Cl: C, 62.64; H, 



















Yield 67%; White solid; mp 178−180 °С; FT-IR (KBr pill, ν cm–1): 3232 (NH), 1770, 1720 
(C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm = 8.68 (s, 1H, NH), 7.52 (d, J = 8.4 Hz, 2H, 
−C6H4−), 7.17 (d, J = 8.4 Hz, 2H, −C6H4−), 4.47 (s, 2H, −CH2−), 1.85−1.55 (m, 12H), 
−C7H12−); 
13C NMR (50 MHz, DMSO−d6): δ/ppm: 178.0, 155.6, 136.6, 131.7, 129.7, 120.7, 
63.9, 40.5, 37.1, 28.9, 22.3; Elemental anal. calc. (%) for C16H19N2O2Br : C, 54.71; H, 5.45; 
N, 7.98; found: C, 54.68; H, 5.48; N, 8.03. 
 
3-(4-Cyanobenzyl)-1,3-diazaspiro[4.5]decane-2,4-dione (2f) 
Yield 53%; White solid; mp 171−173 °С; FT-IR (KBr pill, ν cm–1): 3239 (NH), 1772, 1720 
(C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm =  8.73 (s, 1H, NH), 7.81 (d, 2H,  J = 8 Hz, 
−C6H4−), 7.38 (d, 2H, J = 10 Hz, −C6H4−), 4.59 (s, 2H, −CH2–), 1.85−1.56 (m, 12H, 
−C7H12−); 
13C NMR (50 MHz, DMSO−d6): δ/ppm: 178.0, 155.5, 142.8, 132.9, 128.2, 118.9, 
110.5, 64.1, 40.8, 37.1, 28.9, 22.3; Elemental anal. calc. (%) for C17H19N3O2: C, 68.67; H, 
6.44; N, 14.13; found: C, 68.64; H, 6.49; N, 14.09.  
 
3-(4-Nitrobenzyl)-1,3-diazaspiro[4.5]decane-2,4-dione (2g) 
Yield 73%; Yellow solid; mp 166−169 °С; FT-IR (KBr pill, ν cm–1): 3229 (NH), 1772, 1710 
(C=O); 1H NMR (200 MHz, DMSO−d6): δ/ppm = 8.75 (s, 1H, NH), 8.20 (d, 2H, J = 10 Hz, 
−C6H4−), 7.47 (d, 2H, J = 8 Hz, −C6H4−), 4.64 (s, 2H, –CH2–), 1.86−1.56 (m, 12H, 
−C7H12−); 
13C NMR (50 MHz, DMSO−d6): δ/ppm = 178.0, 155.5, 147.1, 144.8, 128.5, 
124.1, 64.1, 40.6, 37.1, 28.9, 22.3; Elemental anal. calc. (%) for C16H19N3O4: C, 60.56; H, 
6.03; N, 13.24; found: C, 60.52; H, 6.08; N, 13.20. 
 
3-(2-(4-Fluorophenyl)-2-oxoethyl)-1,3-diazaspiro[4.6]undecane-2,4-dione (2h) 
Yield 43%; White solid; mp 140−142 °C; FT-IR (KBr pill, ν cm–1): 3287 (NH), 1769, 1714, 
1700 (C=O); 1H NMR (400 MHz, DMSO−d6): δ/ppm = 8.73 (s, 1H, NH), 8.14 (q, 2H, J = 
2.8 Hz, −C6H4−), 7.42 (t, 2H, J = 8.8 Hz, −C6H4−), 4.92 (s, 2H, –CH2–), 1.95−1.59 (m, 12H, 
−C7H12−); 
13C NMR (100 MHz, DMSO−d6): δ/ppm = 191.5, 178.4, 166.0 (d, J = 255 Hz), 
155.7, 131.7 (d, J = 9.0 Hz), 131.4 (d, J = 2.8 Hz), 116.6 (d, J = 22 Hz), 64.5, 37.4, 29.2, 
22.2. Elemental anal. calc. (%) for C17H19N2O3F: C, 64.14; H, 6.02; N, 8.80; found: C, 64.10; 


















Yield 47%; White solid; mp 206−208 °C; FT-IR (KBr pill, ν cm–1): 3231 (NH), 1775, 1714, 
1700 (C=O); 1H NMR (400 MHz, DMSO−d6): δ/ppm = 8.72 (s, 1H, NH),  8.17 ̶ 8.10 (m, 2H, 
−C6H4−), 7.46 ̶ 7.37 (m, 2H, −C6H4−), 4.91 (s, 2H, –CH2–), 1.96−1.59 (m, 12H, −C7H12−); 
13C NMR (100 MHz, DMSO−d6): δ/ppm = 192.2, 178.4, 155.8, 139.3, 133.2, 130.5, 129.6, 
64.5, 44.7, 37.4, 28.9, 22.5. Elemental anal. calc. (%) for C17H19N2O3Cl: C, 60.99; H, 5.72; 
N, 8.37; found: C, 60.90; H, 5.76; N, 8.33. 
 
3-(2-(4-Fluorophenyl)-2-oxoethyl-5,5-diphenylimidazolidine-2,4-dione (3h) 
Yield 45%; White solid; mp 244−245 °C; FT-IR (KBr pill, ν cm–1): 3233 (NH), 1780, 1704, 
1690 (C=O); 1H NMR (400 MHz, DMSO−d6): δ/ppm = 9.80 (s, 1H, NH), 8.16 (q, 2H, J = 
3.2 Hz, −C6H4−), 7.47−7.37 (m, 12H, 2×C6H5 and −C6H4− ), 5.07 (s, 2H, −CH2−); 
13C NMR 
(100 MHz, DMSO−d6): δ/ppm = 191.3, 173.9, 166.1 (d, J = 252 Hz), 155.3, 140.0, 131.8 (d, 
J = 9.6 Hz), 131.2 (d, J = 2.8 Hz), 129.0, 128.7 , 127.4, 116.6 (d, J = 22 Hz), 70.2, 45.3. 
Elemental anal. calc. (%) for C23H17N2O3F: C, 71.13; H, 4.41; N, 7.21; found: C, 71.09; H, 
4.46; N, 7.18.  
 
3-(2-(4-Chlorophenyl)-2-oxoethyl-diphenylimidazolidine-2,4-dione (3i) 
Yield 43%; White solid; mp 241−242 °C; FT-IR (KBr pill, ν cm–1): 3219 (NH), 1780, 1705, 
1692 (C=O); 1H NMR (400 MHz, DMSO−d6): δ/ppm = 9.83 (s, 1H, NH), 8.13 (d, 2H, J = 
8.4 Hz, −C6H4−), 7.71 (d, 2H, J = 8.4 Hz, −C6H4−), 7.49−7.42 (m, 10H, 2 × C6H5), 5.13 (s, 
2H, −CH2−); 
13C NMR (100 MHz, DMSO−d6): δ/ppm = 191.9, 173.8, 155.3, 140.0, 139.7, 
133.2, 130.6 , 129.6, 129.0, 128.7, 127.4, 127.1, 126.6, 70.2, 45.4; Elemental anal. calc. (%) 
for C23H17N2O3Cl: C, 68.23; H, 4.23; N, 6.92; found: C, 68.20; H, 4.26; N, 6.89. 
 
2.2. Biological characterization 
2.2.1. Compounds and solutions 
The RPMI 1,640 cell culture medium, fetal bovine serum (FBS), and MTT were purchased 
from Sigma Chemical Company, USA. MTT was dissolved (5 mg cm-3) in phosphate 


















Normal rat peritoneal macrophages and tumor cell lines including human colon cancer (HCT-
116), leukemia (K562) and human breast cancer (MDA-MB-231) cell lines were maintained 
in a culture using a nutrient medium RPMI 1640 with 10 % FBS and antibiotics. 
 
2.2.3. Treatment of peritoneal macrophages for evaluation of cytotoxic effect 
The biocompatibility testing of the newly synthesized compounds is the first step in their 
biological characterization. The rat peritoneal macrophages were used for the evaluation of 
biocompatibility. Rat peritoneal macrophages were sded in 96-well flat-bottomed microtiter 
plate and cultivated in 0.1 cm3 of full culture media during 24 h. After that, the investigated 
compounds were added to cells in the final concentrations (0.01, 0.1, 1, 10, and 100 µmol dm-
3), except in the control wells, where only the medium was added. Thusly prepared cell 
cultures were incubated during an additional 24 h. The stock solutions of the compounds were 
prepared in DMSO and dissolved in the corresponding medium to the required working 
concentrations. The effects of the investigated compounds on the viability/proliferation of 
peritoneal macrophages was determined 24 hours later by the MTT test [25], modified by 
Ohno and Abe [26]. Briefly, 0.02 cm3 of MTT dye (5 mg cm-3) was added to each well. After 
incubation for further 3 h, 0.1 cm3 of 10 % sodium dodecyl sulfate was added to extract he 
insoluble product formazan resulting from conversion of the MTT dye by viable cells. The 
number of viable cells in each well is proportional to the intensity of the absorbance of light, 
which was then read in an ELISA plate reader at 570 nm.  
2.2.4. Treatment of cell lines for antiproliferative in vitro screening 
The target cells HCT–116 (10000 cells per well), K562 (100000 cells per well) and MDA–
MB–231 (100000 cells per well) were seeded in triplicate into a wells of a 96-well, flat-
bottomed microtiter plate in 0.1 cm3 culture medium. Twenty-four hours later, after thecell 
adaptation and adherence for both cell lines, 0.1 cm3 of the investigated compound was 
added to cells in the final concentration (0.01, 0., 1, 10 and 100 µmol dm-3), except in the 
control wells, where only culture medium was added to the cells and was incubated during 
additional 24 h. The effect of the investigated comp unds on cancer cell survival was 
determined after 24 h by the MTT test described in the previous section. The antiproliferative 
effect of the compounds was expressed as a percentage of inhibition of proliferation of non-















of the compounds. 
 
2.3. X-ray structure determination 
Single-crystal X-ray diffraction data were collected at room temperature (295 K) on an 
Oxford Gemini S diffractometer equipped with CCD detector using monochromatized Mo Kα 
radiation (λ = 0.71073 Å). Intensities were corrected for absorpti n using the multi-scan 
method. Both structures were solved by direct methods (SIR92) [27] and refined on F2 by 
full-matrix least-squares using the programs SHELXL-97 (1c) [28], SHELXL 2018-3 (2a) 
[29] and WinGX [30]. All non-hydrogen atoms were refin d anisotropically. The positions of 
H atoms connected to C atoms in 1c and to C and N atoms in 2a were calculated on 
geometric criteria and refined using the riding model with Uiso = 1.2Ueq(C,N). The hydrogen 
atom bonded to N1 in 1c was found in ∆F maps and added to the structural models before the 
final cycle of refinement with the fixed positional nd atomic displacement parameters. The 
selected crystal data and refinement results for 1c and 2a are listed in Table 1. The 
crystallographic data for 1c and 2a were deposited at the Cambridge Crystallographic Data 




2.4. Computational details 
All DFT calculations were performed using the Gaussian 09 program package [31] with 
B3LYP method [33] and 6-311++G(d,p) basis set. The default convergence criteria were 
used without any constraint on the geometry. The stability of the optimized geometry was 
confirmed by frequency calculations, which gave real values for all frequencies. The solvent 
effect was introduced by the Conductor Polarizable Continuum Model (CPCM) [33]. 
UV absorption energies of these compounds were calculated by TD-DFT B3LYP 
method in ethanol as solvent. The frontier molecular orbital energies and energy gap of the 
investigated compounds are also calculated at the same level of DFT theory. The GaussView 




















3. Results and Discussion  
3.1 Antiproliferative evaluation 
The antiproliferative potential of the investigated compounds was evaluated against HCT-
116, K562 and MDA-MB-231 cancer cell lines. The cytotoxicity assays against tumor cell 
lines were performed in vitro with various concentrations of compounds [35]. The results for 
each compound were reported as the percentage of inhibit on of treated cells prolifertion 
compared to the non-treated control cells. First of all, the in vitro screening data have 
revealed that all investigated compounds are non-toxic  normal cells. On the other side, all 
investigated compounds demonstrate a statistically significant antiproliferative potential 
against to different tumor cells in the investigated concentration range. 
The investigated compounds exhibit mild to moderate inhibitory effects against 
proliferation of all three investigated tumor cell lines at concentration of 100 µmol dm-3 
(Figs. 2–4 and Tables S1–S5 (Electronic Supplementary Information)). Some general 
conclusions concerning structure–activity relationship  of the investigated compounds 
cannot be simply drawn from the data shown in Figs. 2–4. When the substituent X is the 
same, the increase in the size of the cycloalkyl group mostly results in decrease of the 
antiproliferative activity. Exceptions from this trend were largely observed with inhibition of 
HCT-116 cell proliferation. The parent compounds 1a and 2a appear to be the least active 
ones, while the substitution on the benzyl moiety with the methoxy, chloro or bromo group 
potentiates the antiproliferative activity. Regarding the inhibition of HCT-116 and K562 
tumor cell proliferation, the introduction of the methyl group does not produce an improved 
antiproliferative activity relative to the parent compounds. Based on this, we may postulate 
that, in these cases, effects of the electron-rich substituent X (attraction or repulsion) may 
cause either a tighter interaction or a loosening of the contacts to the amino acid residues in 
the binding pocket of the protein involved in mediating their antiproliferative action. These 
impacts alter its function, thus resulting in the increased antiproliferative activity relative to 
the parent compounds. The replacement of the bridging methylene group with the oxoethyl 
group can result in compounds with a lower antiprolferative activity. However, some 




















3.2. Crystal structures of compounds 1c and 2a 
Compounds 1c and 2a crystallize in monoclinic systems, but in different space groups: P21/c 
for 1c and P21/n for 2a. The asymmetric units of compounds together with atomic numbering 
scheme are presented in Fig. 5. The hydantoin and cyclohexane (C5–C10) rings in 1c are 
almost perpendicular, with dihedral angle of 89.5(1)°. The analogous angle for the 
cycloheptane (C5–C11) ring in 2a is similar and amounts 89.1(1)°. Both cyclohexane d
cycloheptane rings adopt a distorted chair conformation and the maximal deviations from 
their corresponding planes are: 0.256(2) Å for C9 atom in 1c and 0.382(2) for C7 atom in 2a. 
The hydantoin ring in 1c is more planar than the same ring in 2a, where maximal deviations 
are 0.0148(1) Å for N3 and 0.0181(7) Å for C4. The selected bond lengths, angles and 
torsion angles for both compounds are listed in Table 2. The values are similar with 





The molecules of 1c are linked by strong intermolecular N–H···O hydrogen bonds 
(Table 3) between N1 atom, which belongs to the hydantoin ring of one molecule and O2 
atom from the hydantoin ring of an adjacent molecul, permitting the formation of infinite 
pseudo-chains along [010] direction (Fig. 6). The formation of supramolecular chains is not 
unusual for these compounds and the chains have been found in crystal packing of similar 
hydantoin derivatives [22]. The neighboring chains are further stabilized by weak C–H···π 
interactions (H···Cg distance is 2.860 Å) between H18 atom from the metoxy group and the 
adjacent phenyl ring (Fig. 7) and together with numerous C–H···O contacts (Table 3) 
construct a three-dimensional network. 
By intermolecular N–H···O hydrogen bonds (Table 3 and Fig. 8), the molecules of 2a 
are connected into centrosymmetric dimmers parallel to the b-axis. The formation of the 
centrosymmetric dimmers are not rare for this type of compounds and they are found in 
similar systems [22, 36, 37]. The crystal packing of 2a is stabilized by the C–H···O 
interactions (Table 3), while additional weak C–H···π interactions (H···Cg distance is 2.940 
Å) between H16 atom from one phenyl ring and the π-system of the adjacent phenyl ring 
























Both introduction of different substituents X and change in the size of the cycloalkyl 
group produce a variety in their crystal structures. Despite N–H···O hydrogen bonds 
dominate, weak interactions promote either stabilizat on of the crystal structure or its 
alteration. Regarding compounds 1d and 1e, we have previously reported that halogen 
bonding (X···O) interactions form a supramolecular pseudo-hexagonal network [37]. On the 
other side, compounds 2d and 2e build a different crystal packing based on the X···π 
interactions. It is clear that tailoring the crystal structure of the investigated compounds 
through the proposed structural changes should be taken into account when considering their 
biopharmaceutical aspects, especially those related to their low aqueous solubility. Poorly 
soluble compounds can provide a risk of low bioavail bility with consequences for safety 
and efficacy. However, a comprehensive knowledge of drugs at the molecular level is 
required to determine the appropriate approach to improving solubility and dissolution rate. 
 
3.3. Molecular geometry 
By applying the DFT method at B3LYP/6-311++G(d,p) level of theory, the optimized 
geometry parameters for all investigated cycloalkanespiro-5-hydantoines were determined. 
The most significant geometric parameters (bond lengths, bond angles and torsion angles) 
are listed in Tables S6 and S7 (Electronic Supplementary Information).  
According to the DFT calculations, the cycloheptanespiro-5-hydantoine derivatives 
exist in two conformational forms relative to each ot er as 81:19. The first form is presented 
in Fig. 10, while in the other form the cycloheptane rings occupies a stable conformation of 
the distorted chair (Fig. S1, Electronic Supplementary Information). The difference in energy 



















which is evident from the N–C bond lengths (N1–C2, N1–C5, N3–C2 and N3–C4, Table S6 
and S7, Electronic Supplementary Information) [38]. The substituent effect is reflected on 
small changes of length of bonds bridging the hydantoin and phenyl rings. An increase of the 
electron accepting ability of the substituent X is associated with a shortening of the N–C11 
bond in the compounds of series 1 and the N–C12 bond in the compounds of series 2, 
contrary to the case of the electron donating substit ents, where a slight lengthening is 
observed. On the other side, the C11–C12 bond in the compounds of series 1 and the C12–
C13 bond in the compounds of series 2 lengthen along with an increase of the electron 
accepting ability of the substituent X when compared to the parent compounds. The electron 
donating substituents have an opposite effect. The planes defined by the hydantoin and 
cycloalkyl rings are approximately perpendicular to each other. The situation is similar 
regarding the relative orientation of the hydantoin and phenyl rings (Table 2). 
When comparing the crystallographically determined structure and structure 
calculated by the DFT methods, it can be seen that the main differences result from the 
different bond lengths and bond angles in the cycloalkane ring (the difference ranges from 
0.012 to 0.033 A). This can be attributed to so-called packing effects, which distort the 
structures. Analogously, a notable difference in the length of the N1–C2 and N1–C5 bonds 
can be ascribed to the involvement of the N1 atom in various intermolecular interactions, 
primarily hydrogen bonding, which is not present in the isolated state, i.e. in the DFT 
calculations. Furthermore, the differences found in the relative orientation of the hydantoin 
and lipophilic cycloalkyl and phenyl groups in the crystal and as an isolated molecule 
indicate that these molecules can easily change their conformation upon binding to a protein. 
 
3.5. Experimental and theoretical study of electronic absorption spectra 
The absorption spectra of the investigated compounds retain essentially the character of those 
of 3-(4-substituted benzyl)-1,3-diazaspiro[4.4]nonane-2,4-diones [36]. Only the absorption 
spectra of the compounds of series 2 in ethanol are given here (Fig. 11 and Table 4), because 
both series of compounds (1 and 2) exhibit the same trends in λmax as a function of the nature 
of the substituent X and no significant solvatochromic shift was observed. Their main feature 
is an intense absorption band with a shoulder on the low-energy side in the region of 207–



















When the donating or accepting ability of the substituent X increases, a red shift of 
the absorption maxima is observed. It is evident that, because of the C,H-hyperconjugation of 
the bridging CH2 group, the chromophoric system involves both hydantoin and aryl moieties. 
To understand the shift of this band under the influence of the substituent X, the data from 




There is a split in the Hammett plot at the parent compound, whereby the electron-
donating effect is somehow stronger than electron accepting effect (ρ = +12.4 vs. ρ = –10.8). 
When the substituent X is a resonance electron-accepting substituent (NO2 and CN), the data 
fall distinctly off the linear relationship, as expected.  
The UV-Vis absorption spectra for representative comp unds were calculated in 
relation to their optimized geometry by applying the B3LYP method with 6-311++G(d,p) 
basic set (Fig. 13, Table S8). Solvent effects were d t rmined using the TD-DFT method.  
In the compound 2c with the electron-donating methoxy group, a closer look into the 
two major transitions (HOMO→LUMO+2 and HOMO→LUMO+4) based on the shape of 
the molecular orbital in Fig. 13a suggests a typical π→π* character. When the substituent X 
is the electron-accepting NO2 group (compound 2g), a higher amount of the orbital 
distribution is observed on the aryl moiety in the LUMO orbital. Thus, charge may transfer in 
the HOMO–2→LUMO and HOMO–1→LUMO transitions resulting in the observed 
absorption bands (Fig. 13b). 
<Figure 13> 
 
The orbital distributions of their HOMOs and LUMOs are presented in Fig. 14. The 
HOMO energy describes the region of a molecule, which can donate electrons during the 
formation of complexes with proteins involved in mediating its biological effects. On the 
other hand, the LUMO energy refers to its ability to accept the electrons from proteins [39]. 
In the case of the parent compounds (1a and 2a) or when X is an electron-donating 
substituent, the HOMOs mainly involve contributions of π-orbitals of the aryl moiety, while 















the opposite effect: the HOMOs are distributed over th  entire molecule, while the LUMOs 
are shifted towards the aryl moiety. In the case of the compounds with the bridging oxoethyl 
group, the HOMOs extend mainly over the hydantoin ring, while the LUMOs are mainly 
composed of those π orbital from the aryl moiety. The HOMO–LUMO energy aps are in 
the range from 4.4 to 6.3 eV (Table 5). The larger HOMO–LUMO energy gaps of the 
investigated compounds refer to their higher kinetic s ability and lower chemical reactivity. 
In comparison with the parent compounds, the electron-donating substituents X elevate both 
HOMO and LUMO energy levels simultaneously. Oppositely, the HOMO and LUMO 
energy levels are lower than that of the parent compounds, when X is a resonance electron-
accepting substituent (NO2 and CN). With enlarging the cycloalkane ring, the energy gap 
remains almost unchanged. 
<Figure 14> 
<Table 5> 
3.6 ’Rule of five’ properties 
 
The Lipinski rule of five is widely used to estimate drug-like properties [40]. According to 
this rule, compounds with good permeability have log P < 5, molecular weight < 500 g mol-
1, the number of hydrogen bond acceptors < 10 and the number of hydrogen bond donors < 
5. 
The analysis of molecular descriptors shows that the investigated compounds obey 
rule of five (Table 5). When compared to the phenytoin derivatives [22], the physico-
chemical properties of the investigated compounds are moving towards somewhat lower 
molecular weight (258–335), and coincidentally also somewhat lower lipophilicity (2.6–3.8). 
As expected, lipophilicity increases with the size of the cycloalkyl group. With the exception 
of the methoxy group, the introduction of the substituent X results in the increase of 
lipophilicity relative to the parent compounds (1a and 2a). This will lead to their higher 
partitioning into the lipophilic phase of a biological membrane or lipophilic domains of a 
protein. Furthermore, a higher local concentration of the investigated compounds can be 
expected near a binding site, but it does not necessarily indicate its higher biological activity. 
On the other side, lipophilicity decreases when the bridging methyl group is replaced with 
the ethyloxo group. The investigated compounds contain both proton acceptor and proton 
donor groups, which indicates their high capacity for hydrogen bonding, especially toward 















compounds is almost constant and low, thus indicating that large changes of their 
conformation upon binding to a binding site are notexpected. An increase in polar surface 
area (PSA) of the investigated compounds arises from b th introduction of the substituent X 
and replacement of the bridging methyl group with the ethyloxo group. Generally, relatively 





In the present paper, we reported the synthesis and antiproliferative evaluation of two series 
cycloalkanespiro-5-hydantoins with a 4-substituted benzyl or a 2-(4-substituted phenyl)-2-
oxoethyl group at N3 position. For comparison, we also described the 5,5-diphenylhydantoin 
analogues. The investigated compounds exhibited mild to moderate effects against 
proliferation of human colon (HCT-116), leukemia (K562) and breast (MDA-MB-231) 
cancer cell lines at concentration of 100 µmol dm-3, while they were non-toxic to normal 
cells. Some interesting structure–activity findings were revealed. The substitution on the 
benzyl moiety with the methoxy, chloro or bromo group potentiated the antiproliferative 
activity relative to the parent compounds, while an increase in the size of the cycloalkyl 
group resulted in a decrease in the antiproliferative activity in most cases. The replacement 
of the bridging methylene group with the oxoethyl group can result in compounds with a 
lower antiproliferative activity. The investigated compounds were compatible with the ’rule 
of five’ indicating that they have satisfactory pharm cokinetic properties and bioavailability. 
Regarding the crystallographic analysis, the investigated compounds adopted 
different packing arrangements, either hydrogen bonded dimeric units or one-dimensional 
pseudo-chains. Controlling the crystal structure of the investigated compounds through the 
proposed structural changes should be taken into account when considering their 
biopharmaceutical aspects, especially those related to their low aqueous solubility. The 
theoretical calculations reproduced the experimental data well, thus describing the geometry 
and electronic structures accurately and providing etailed spectroscopic results. 
We find that the presented results shed light on the s rategy for development of new 
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Fig. 1. Chemical structures of the investigated 1,3-diazaspiro[4.5]decane-2,4-diones (Series 
1, labeled as 1a–1i), 1,3-diazaspiro[4.6]undecane-2,4-diones (Series 2, labeled as 2a–2i), and 
5,5-diphenylhydantoins (Series 3, labeled as 3a–3i). 
Fig. 2. The effect of he investigated compounds against prolife ation of the HCT–116 cell 
line at concentration 100 µmol dm-3. Data for the compounds 3a–3e were taken from our 
previous paper [22]. 
Fig. 3. The effect of the investigated compounds against prolife ation of the K562 cell line at 
concentration 100 µmol dm-3.  
Fig. 4. The effect of the investigated compounds against prolife ation of the MDA–MB–231 
cell line at concentration 100 µmol dm-3. Data for the compounds 3a–3e are taken from our 
previous paper [22]. 
Fig. 5. The asymmetric units of 1c and 2a. Displacement ellipsoids are drawn at 30% 
probability level and hydrogen atoms are shown as small spheres of arbitrary radii. 
Fig. 6. The polymeric pseudo-chain of 1c along the b-axis formed by hydrogen bonds 
(dashed lines). The hydrogen atoms are omitted for clarity. 
Fig. 7. C–H···π interactions (dot lines) between adjacent chains in 1c. 
Fig. 8. The centrosymmetric dimer of 2a. Symmetry code, (i): –x+1, –y, –z. 
Fig. 9. The crystal packing diagram of 2a in the almost ac-plane. Hydrogen bonds and C–
H···π interactions are presented with dash and dot lines, respectively. 
Fig. 10. The most stable conformations of compounds 1a and 2a. 
Fig. 11. The absorption spectra of the compounds 2a–2g at concentration ~1.0×10–5 
mol dm-3 in ethanol. 
Fig. 12. Relationships between νmax and σp for the investigated 3-(4-substituted benzyl)-1,3-
diazaspiro[4.6]undecane-2,4-diones (series 2). 
Fig. 13. Experimental (dashed line) and simulated (full line) UV-Vis absorption spectra of 
the compounds 2c (a) and 2g (b) in ethanol. 
Fig. 14. The molecular orbitals and energy gaps between HOMO and LUMO of compounds 
2a, 2c, 2g and 2i in the gas phase calculations. 
Scheme 1. Synthesis of the investigated cyclohexanespiro-5-hydantoine derivatives (1a–1g) 
and cycloheptanespiro-5-hydantoine derivatives (2a–2g). 
Scheme 2. Synthesis of the investigated cycloalkanespiro-5-hydantoine derivatives (1h, 1i, 













Table 1. Crystal data and structure refinements for 1c and 2a. 
Compound 1c 2a 
Formula C16H20N2O3 C16H20N2O2 
Formula weight (g mol-1) 288.34 272.34 
Crystal size (mm3) 0.42×0.34×0.05 0.87×0.31×0.10 
Crystal system Monoclinic Monoclinic 
Space group P21/c P21/n 
a (Å) 13.681(3) 12.783(3) 
b (Å) 11.474(2) 6.2750(13) 
c (Å) 10.089(2) 18.635(4) 
β (°) 110.76(3) 105.94(3) 
V (Å3) 1480.9(5) 1437.3(5) 
Z 4 4 
F(000) 616 584 
µ (mm-1) 0.090 0.084 
ρc (g cm
-3) 1.293 1.259 
θ range (º) 3.18–25.35 3.32–26.02 
Index ranges, 







R indices (all data) 0.0723i 0.0603ii 
Goodness-of-fit 1.068 1.067 
Rint 0.0221 0.0227
 
∆ρmax, ∆ρmin (e Å
-3) 0.133, –0.193 0.292, –0.321 
i w = 1 / [s2(Fo
2) + (0.0392P)2 + 0.1715P] where P = (Fo
2 + 2Fc
2)/3; 
ii w = 1 / [s2(Fo




























Table 2. The experimental and calculated values of selected bond lengths, bond angles and 
torsion angles for compounds 1c and 2a. 
Parameter 1c (exp.) 1c 
(calc.) 




Bond lengths (Å)   Bond length (Å)    
N1−C2 1.342(2) 1.367 N1−C2 1.337(2) 1.366 1.367 
N1−C5 1.460(2) 1.466 N1−C5 1.455(2) 1.468 1.467 
C2−O1 1.215(2) 1.212 C2−O1 1.224(2) 1.212 1.212 
C2−N3 1.405(2) 1.413 C2−N3 1.391(2) 1.413 1.413 
N3−C4 1.358(2) 1.375 N3−C4 1.369(2) 1.376 1.376 
C4−O2 1.220(2) 1.212 C4−O2 1.206(2) 1.212 1.212 
C4−C5 1.516(2) 1.539 C4−C5 1.526(2) 1.543 1.543 
C5−C6 1.531(2) 1.543 C5−C6 1.539(3) 1.545 1.545 
C5−C10 1.525(3) 1.546 C5−C11 1.527(3) 1.553 1.548 
C6−C7 1.519(3) 1.534 C6−C7 1.506(3) 1.539 1.538 
C7−C8 1.517(3) 1.535 C7−C8 1.508(5) 1.538 1.538 
C8−C9 1.515(2) 1.535 C8−C9 1.482(4) 1.534 1.543 
C9−C10 1.518(3) 1.535 C9−C10 1.510(3) 1.538 1.540 
N3−C11 1.464(2) 1.468 C10−C11 1.520(3) 1.538 1.538 
C11−C12 1.502(2) 1.513 N3−C12 1.447(2) 1.466 1.466 
C12−C13 1.376(3) 1.394 C12−C13 1.509(3) 1.516 1.516 
C12−C17 1.376(3) 1.402 C13−C14 1.377(3) 1.399 1.399 
C13−C14 1.375(2) 1.396 C13−C18 1.379(3) 1.398 1.398 
C14−C15 1.378(3) 1.397 C14−C15 1.379(3) 1.393 1.393 
C15−C16 1.373(3) 1.400 C15−C16 1.367(3) 1.395 1.395 
C16−C17 1.388(3) 1.387 C16−C17 1.372(3) 1.394 1.394 
   C17−C18 1.389(3) 1.394 1.394 
Bond angles (°)   Bond angles (°)    
N1−C5−C4 100.6(1) 100.7 N1−C5−C4 100.6(1) 100.3 100.4 
N1−C5−C10 112.5(1) 112.5 N1−C5−C11 111.2(2) 109.7 111.4 
C4−C5−C10 111.7(2) 110.0 C4−C5−C11 109.0(1) 109.5 108.7 
N1−C5−C6 112.1(1) 112.4 N1−C5−C6 111.7(2) 112.3 112.2 
C4−C5−C6 109.1(1) 110.3 C4−C5−C6 108.0(2) 108.8 108.0 
C6−C5−C10 110.4(1) 110.6 C6−C5−C11 115.4(2) 115.1 114.9 
Torsion angles (°)   Torsion angles (°)    
C4−N3−C11−C12 81.3(2) 91.8 C4−N3−C12−C13 –84.7(2) −88.0 −86.0 
N3−C11−C12−C13 –99.3(2) –88.2 N3−C12−C13−C14 –11.3(2) −85.2 −84.9 
N1−C5−C6−C7 71.7(2) 72.8 N1−C5−C6−C7 65.9(2) 165.4 76.0 
C4−C5−C6−C7 –177.6(2) –175.8 C4−C5−C6−C7 175.6(2) –85.4 −174.2 
N3−C4−C5-C10 120.7(2) 121.7 N3−C4−C5−C11 119.1(2) 122.8 120.2 
C2−N3−C11−C12 −102.3(2) –88.1 C2−N3−C12−C13 101.0(2) 90.6 92.2 
iRegarding the optimized conformations, the DFT calculations reveal two energetically close forms of 2a (Fig. S1, 
















Table 3. The geometry of possible hydrogen bonds for compounds 1c and 2a. 
Compound D – H···A 




d(H···A) (Å) D – H···A (°) 
1c 
N1–H19···O2i 0.846(1) 2.993(2) 2.149(1) 176(2) 
C18–H18A···O1ii 0.960 3.608(3) 2.678 163 
C8–H8A···O1iii 0.970 3.564(2) 2.682 151 
C7–H7B···O2i 0.970 3.636(2) 2.763 150 
C9–H9A···O2i 0.970 3.641(3) 2.772 149 
C10–H10B···O1iii 0.970 3.640(2) 2.793 146 
C10–H10A···O2iv 0.970 3.673(2) 2.842 144 
2a 
N1–H1···O1i 0.860 2.928(2) 2.07 173 
C7–H7A···O1ii 0.970 3.736(3) 2.772 173 
C7–H7B···O1i 0.970 3.893(3) 2.943 167 
C10–H10B···O1i 0.970 3.917(2) 2.975 164 
C11–H11A···O2iii 0.970 3.472(2) 2.734 133 
Symmetry codes: 1c, (i): –x+1, y–1/2, –z+3/2; (ii): –x, y+1/2, –z+1/2; (iii): –x+1, y+1/2, –z+3/2; 
(iv): x, –y+1/2, z–1/2; 2a, (i): –x, –y+1, –z+1; (ii): –x, –y, –z+1; (iii): –x+1/2, y+1/2, –z+3/2. 
 
Table 4. UV-Vis spectral data for the compounds 2a–2g in ethanol 
Compound 2a 2b 2c 2d 2e 2f 2g 


























Table 5. Calculated energies of the HOMO and LUMO orbitals and energy gap for compounds 
1a–1i and 2a–2i in the gas phase and ethanol.  
Compound Gas phase Ethanol 





1a −6.98 −0.69 6.26 −7.13 −0.84 6.29 
1b −6.67 −0.63 6.04 −6.81 −0.74 6.07 
1c −6.19 −0.59 5.60 −6.37 −0.74 5.63 
1d −6.90 −0.91 5.99 −7.03 −0.99 6.04 
1e −6.83 −0.95 5.88 −6.95 −1.02 5.93 
1f −7.45 −1.84 5.61 −7.41 −1.83 5.58 
1g −7.68 −2.86 4.82 −7.49 −3.10 4.39 
1h −7.33 −2.16 5.17 −7.44 −2.22 5.21 
1i −7.34 −2.29 5.05 −7.39 −2.34 5.05 
2a −6.97 −0.64 6.33 −7.09 −0.76 6.31 
2b −6.68 −0.58 6.09 −6.81 −0.69 6.12 
2c −6.20 −0.55 5.66 −6.37 −0.70 5.67 
2d −6.91 −0.91 6.00 −7.02 −0.99 6.03 
2e −6.83 −0.95 5.89 −6.96 −1.02 5.93 
2f −7.44 −1.84 5.60 −7.42 −1.87 5.54 
2g −7.65 −2.86 4.79 −7.48 −3.13 4.35 
2h −7.33 −2.18 5.15 −7.43 −2.22 5.21 












































1a 258.32 2.79 1 4 2 74.50 0 
1b 272.35 3.07 1 4 2 73.70 0 
1c 288.35 2.51 1 5 3 94.40 0 
1d 292.77 3.35 1 4 2 77.80 0 
1e 337.22 3.62 1 4 2 76.90 0 
1f 283.33 2.93 1 5 2 135.9 0 
1g 303.32 2.82 1 7 3 167.7 1 
1h 304.32 2.13 1 5 3 110.00 0 
1i 320.78 2.53 1 5 3 110.00 0 
2a 272.35 3.21 1 4 2 74.60 0 
2b 286.38 3.49 1 4 2 77.70 0 
2c 302.37 2.93 1 5 3 93.10 0 
2d 306.79 3.77 1 4 2 75.30 0 
2e 351.24 4.04 1 4 2 77.10 0 
2f 297.36 3.35 1 5 2 129.8 0 
2g 317.35 3.24 1 7 3 169.2 1 
2h 318.35 2.55 1 5 3 107.7 0 
2i 334.80 2.95 1 5 3 108.5 0 
3aiv 342.40 4.41 1 4 4 69.26 0 
3biv 356.43 4.69 1 4 4 68.17 0 
3civ 372.42 4.13 1 5 5 85.08 0 
3div 376.84 4.97 1 4 4 68.61 0 
3eiv 421.29 5.24 1 4 4 68.97 1 
3fiv 367.41 4.55 1 5 4 124.9 0 
3giv 387.39 4.45 1 7 5 161.9 1 
3hiv 388.40 3.76 1 5 5 100.6 0 




< 500 < 5 < 5 < 10  < 8 < 140  ≤ 1 
iCalculated with B3LYP\6-311++G(d,p); 
iiA donor indicates any OH or NH groups;   
iiiAn acceptor indicates any O or N including those in do or groups;   





































































































































































































































1. In searching for new hydantoin-based drugs, two series of compounds were synthesized. 
2. Compounds with the CH3O, Cl or Br group exhibited an improved antiproliferative activity. 
3. Different modes of intermolecular aggregation in the crystal structures were identified. 
4. Substituent effects were reflected in the geometries and electronic structures. 
5. The investigated compounds were compatible with the Lipinski rule of five. 
 
